Integra LifeSciences (NASDAQ:IART) Stock Price Down 5.3% – Time to Sell?

Integra LifeSciences Holdings Co. (NASDAQ:IART) shares dropped 5.3% during mid-day trading on Wednesday . The stock traded as low as $24.33 and last traded at $24.32. Approximately 61,246 shares changed hands during trading, a decline of 89% from the average daily volume of 534,235 shares. The stock had previously closed at $25.68.

Analyst Ratings Changes

Several analysts have weighed in on IART shares. Morgan Stanley initiated coverage on Integra LifeSciences in a research report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price objective for the company. Citigroup upped their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a report on Tuesday, November 5th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, Integra LifeSciences presently has a consensus rating of “Hold” and a consensus price target of $23.00.

Integra LifeSciences Stock Down 5.5 %

The company’s fifty day simple moving average is $23.85 and its 200 day simple moving average is $21.84. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The firm has a market capitalization of $1.87 billion, a PE ratio of -269.53, a price-to-earnings-growth ratio of 0.87 and a beta of 1.17.

Insider Buying and Selling at Integra LifeSciences

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the transaction, the executive vice president now owns 56,182 shares in the company, valued at $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 3.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Integra LifeSciences

A number of large investors have recently added to or reduced their stakes in IART. Principal Financial Group Inc. boosted its holdings in shares of Integra LifeSciences by 18.7% in the third quarter. Principal Financial Group Inc. now owns 401,432 shares of the life sciences company’s stock worth $7,294,000 after buying an additional 63,266 shares during the last quarter. Versor Investments LP bought a new position in Integra LifeSciences in the third quarter worth approximately $612,000. BNP Paribas Financial Markets boosted its stake in shares of Integra LifeSciences by 824.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 111,775 shares of the life sciences company’s stock worth $2,031,000 after acquiring an additional 99,685 shares during the last quarter. GSA Capital Partners LLP purchased a new position in Integra LifeSciences during the third quarter valued at $960,000. Finally, State of Alaska Department of Revenue grew its stake in shares of Integra LifeSciences by 144.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 131,751 shares of the life sciences company’s stock valued at $2,393,000 after acquiring an additional 77,825 shares during the period. Institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.